Complete genomic characterization of an intertypic Sabin 3/Sabin 2 capsid recombinant

FEMS Immunology and Medical Microbiology

Volumn 52, Issue 3, 2008, Pages 343-351

  Dedepsidis, Evaggelos ^a   Pliaka, Vaia ^a   Kyriakopoulou, Zaharoula ^a   Brakoulias, Christos ^a   Levidiotou Stefanou, Stamatina ^b   Pratti, Anastassia ^a   Mamuris, Zissis ^a   Markoulatos, Panayotis ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Capsid; Evolution; Poliovirus; Recombination

Indexed keywords

CAPSID PROTEIN;

5' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENOMICS; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SABIN 2 GENE; SABIN 3 GENE; VACCINATION; VIRUS GENE; VIRUS ISOLATION;

ANTIGENS, VIRAL; CAPSID PROTEINS; CHILD; FECES; GENOME, VIRAL; HUMANS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC;

EID: 41049113984     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2008.00381.x     Document Type: Article

References (45)

1. Balanant J, Guillot S, Candrea A, Delpeyroux F Crainic R (1991) The natural genomic variability of poliovirus analyzed by a restriction fragment length polymorphism assay. Virology 184 : 645 654.
2. Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W Heim A (1999) Evolution of poliovirus type 1 during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 265 : 178 184.
3. Belnap DM, McDermott BM, Filman DJ, Cheng N, Trus BL, Zuccola HJ, Racaniello VR, Hogle JM Steven AC (2000) Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc Natl Acad Sci USA 97 : 73 78.
4. Blomqvist S, Skyttä A, Roivainen M Hovi T (1999) Rapid detection of human rhinoviruses in nasopharyngeal aspirates by a microwell reverse transcription-PCR-hybridisation assay. J Clin Microbiol 37 : 2813 2816.
5. Blomqvist S, Bruu AL, Stenvik M Hovi T (2003) Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccine and containing a chimeric capsid protein VP1. J Gen Virol 84 : 573 580.
6. Blomqvist S, Savolainen C, Laine P, Hirttiö P, Lamminsalo E, Penttilä E, Jöks S, Roivainen M Hovi T (2004) Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J Virol 78 : 4876 4883.
7. Caro V, Guillot S, Candrea A, Delpeyroux F Crainic R (2001) Molecular strategy of 'serotyping' of human enterovirus. J Gen Virol 82 : 79 91.
8. Casas I, Powell L, Klapper PE Cleator GM (1995) New method for the extraction of viral RNA and DNA from cerebrospinal fluid for use in the polymerase chain reaction assay. J Virol Methods 53 : 25 36.
9. Cherkasova EA, Korotkova EA, Yakovenko ML, Ivanova OE, Eremeeva TP, Chumakov KM Agol VI (2002) Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J Virol 76 : 6791 6798.
10. Cherkasova EA, Yakovenko ML Rezapkin GV (2005) Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. J Virol 79 : 1062 1070.
11. Colston EM Racaniello VR (1995) Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition. J Virol 69 : 4823 4829.
12. Cuervo NS, Guillot S, Romanenkova N, Combiescu M, Combiescu AA, Seghier M, Caro V, Crainic R Delpeyroux F (2001) Genomic features of intertypic recombinant sabin poliovirus strains excreted by primary vaccines. J Virol 75 : 5740 5751.
13. Dedepsidis E, Karakasiliotis I, Paximadi E, Kyriakopoulou Z, Komiotis D Markoulatos P (2006) Detection of unusual mutation within the VP1 region of different re-isolates of poliovirus Sabin vaccine. Virus Genes 33 : 183 191.
14. Egger D Bienz K (2002) Recombination of poliovirus RNA proceeds in mixed replication complexes originating from distinct replication start sites. J Virol 76 : 10960 10971.
15. Emini EA, Jameson BA, Lewis AJ, Larsen GR Wimmer E (1982) Poliovirus neutralizing epitopes: analysis and location with neutralizing monoclonal antibodies. J Virol 43 : 997 1005.
16. Fricks CE Hogle JM (1990) Cell-induced conformational change in poliovirus: externalisation of the amino-terminus of VP1 is responsible for liposome binding. J Virol 64 : 1934 1945.
17. Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM Agol VI (2000) Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J Virol 74 : 7381 7390.
18. Georgescu MM, Balanant J, Macadam A, Otelea D, Combiescu M, Combiescu AA, Crainic R Delpeyroux F (1997) Evolution of the sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 71 : 7758 7768.
19. Georgopoulou A Markoulatos P (2001) Sabin type 2 poliovirus with intertypic vaccine/vaccine recombinant genomes. Eur J Clin Microbiol Infect Dis 20 : 792 799.
20. Grant RA, Hiremath CN, Filman DJ, Syed R, Andries K Hogle JM (1994) Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr Biol 4 : 784 797.
21. Guest S, Pilipenko E, Sharma K, Chumakov K Ross RP (2004) Molecular mechanisms of attenuation of the sabin strain of poliovirus type 3. J Virol 78 : 11097 11107.
22. Guillot S, Caro V, Cuervo N, Korotkova E, Combiescu M, Persu A, Aubert-Combiescu A, Delpeyroux F Crainic R (2000) Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J Virol 74 : 8434 8443.
23. Harber J, Bernhardt G, Lu HH, Sgro JY Wimmer E (1995) Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor. Virology 214 : 559 570.
24. He Y, Bowman VD, Mueller S, Bator CM, Bella J, Peng X, Baker TS, Wimmer E, Kuhn RJ Rossmann MG (2000) Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci USA 97 : 79 84.
25. Hogle JM, Chow M Filman DJ (1985) Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229 : 1358 1365.
26. Karakasiliotis I, Markoulatos P Katsorchis T (2004) Site analysis of recombinant and mutant poliovirus isolates of sabin origin from patients and from vaccines. Mol Cell Probes 18 : 103 109.
27. Karakasiliotis I, Paximadi E Markoulatos P (2005) Evolution of a rare vaccine-derived multirecombinant poliovirus. J Gen Virol 86 : 3137 3142.
28. Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, Quick L Pallansch MA (1998) Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 36 : 2893 2899.
29. Kew OM, Glasgow VM, Landaverde M et al 2002) Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296 : 356 359.
30. Kew OM, Sutter RW, de Gourville EM, Dowdle WR Pallansch MA (2005) Vaccine-derived poliovirus and the endgame strategy for global polio eradication. Annu Rev Microbiol 59 : 587 635.
31. Li WH, Wu CI Luo CC (1985) A new method of estimating synonymous and nonsynonymous rates of nucleotide substitution considering the relative likelihood of nucleotide and codon changes. Mol Biol Evol 2 : 150 174.
32. Martin J, Dunn G, Hull R, Patel V Minor PD (2000) Evolution of the sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol 74 : 3001 3010.
33. Martin J, Samoilovich E, Dunn G, Lackenby A, Feldman E, Heath A, Svirchevskaya E, Cooper G, Yermalovich M Minor PD (2002) Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis. J Virol 76 : 10921 10928.
34. Minor PD, Ferguson M, Evans DM, Almond JW Icenogle JP (1986) Antigenic structures of polioviruses of serotypes 1, 2 and 3. J Gen Virol 67 : 1283 1291.
35. Mulders MN, Lipskaya GY, van der Avoort HG, Koopmans MP, Kew OM van Loom AM (1995) Molecular epidemiology of wild poliovirus 1 in Europe, the Middle East, and the Indian subcontinent. J Infec Dis 171 : 1399 1405.
36. Mulders MN, Reimerirink JHJ, Stevnik M, Alaeddinoglou I, van der Avoort HGAM, Hovi T Koopmans MPG (1999) A sabin vaccine-derived field isolate of poliovirus type 1 displaying aberrant phenotypic and genetic features, including a deletion in antigenic site 1. J Gen Virol 80 : 907 916.
37. Oberste MS, Maher K, Flemister MR, Marchetti G, Kilpatrick DR Pallansch MA (2000) Comparison of classic and molecular approaches for the identification of untypeable enteroviruses. J Clin Microbiol 38 : 1170 1174.
38. Paximadi E, Karakasiliotis I, Mamuris Z, Stathopoulos C, Krikelis V Markoulatos P (2006) Genomic analysis of recombinant sabin clinical isolates. Virus Genes 32 : 203 210.
39. Rousset D, Andrianarivelo MR, Razafindratsimandresy R, Randriamanalina B, Guillot S, Balanant J, Mauclère P Delpeyroux F (2003) Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infec Dis 9 : 885 887.
40. Shimizu H, Thorley B, Paladin FJ et al 2004) Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J Virol 78 : 13512 13521.
41. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA Hinman AR (1992) Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14 : 568 579.
42. Tatem LM, Weeks-Levy C, Georgiou A, Dimichelle SJ, Gorgacz EJ, Racaniello VR, Cano FR Mento SJ (1992) A mutation present in the amino terminus of sabin 3 poliovirus VP1 protein is attenuating. J Virol 66 : 3194 3197.
43. Westrop GD, Wareham KA Evans DMA (1989) Genetic basis of attenuation of the sabin type 3 oral poliovirus vaccine. J Virol 63 : 1338 1344.
44. Wimmer E, Hellen CUT Cao X (1993) Genetics of poliovirus. Annu Rev Genet 27 : 353 436.
45. Yanovenko ML, Cherkasova EA, Rezapkin GV, Ivanova OE, Ivanov AP, Eremeeva TP, Baykova OY, Chumakov KM Agol VI (2006) Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J Virol 80 : 2641 2653.